Femasys (FEMY) Q2 2026 earnings summary

Executive summary

• Focused on commercializing FDA-cleared and globally approved women's health products, including FemaSeed and FemBloc, with ongoing pivotal clinical trials and recent regulatory milestones in the U.S. and international markets.

• Completed $30 million private placement, with potential for up to $90 million, strengthening financial position and enabling execution of U.S. commercial strategy for fertility portfolio and FemBloc clinical program.

• Announced key corporate developments, including a new COO, strategic partnerships, product launches, and regained compliance with Nasdaq listing requirements.

• Advanced commercial launch of FemaSeed Complete, including initial use and provider awareness campaigns at ACOG 2026 and targeted OB/GYN offices.

• Established international partnership with AMI Technologies for commercialization in Israel.

Financial highlights

• Sales for Q2 2026 were $331,827, down 18.9% year-over-year, mainly due to lower FemVue sales; six-month sales were $756,716, up 0.8% from the prior year, driven by FemaSeed.

• Net loss for Q2 2026 was $4.47 million, compared to $4.59 million in Q2 2025; six-month net loss was $3.6 million, a significant improvement from $10.5 million in the prior year.

• Operating expenses for Q2 2026 increased 28.1% year-over-year to $5.26 million, driven by higher R&D, sales and marketing, and G&A costs; R&D expenses rose 37.6% for the quarter but fell 25.7% for the six months.

• Other income for the quarter was $597,644, reflecting gains from fair value adjustments on derivative liabilities.

• Cash and cash equivalents as of June 30, 2026, were $1.44 million, with an additional $30 million raised in August 2026, and an accumulated deficit of $149.4 million.

Outlook and guidance

• Management expects continued investment in commercialization and clinical development, anticipating ongoing operating losses and negative cash flows.

• Recent capital raise is expected to support strategic priorities, including commercial initiatives, clinical program advancement, and international expansion.